FindTrial
Sign In

Clinical Trial to study the role of Vistabdhajirna (Indigestion) in Sandhigata Vata (Osteo Arthritis)

An Interventional Randomised Comparative Trial To Study The Role Of Vishtabdhajirna In The Pathogenesis Of Sandhigata Vata Using Agnideepana Aushadha As Compared To Standard Ayurveda Treatment Of Sandhigata Vata And Combination Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038879
Enrollment
120
Registered
2021-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M150- Primary generalized (osteo)arthritis

Interventions

None listed

Sponsors

ALL INDIA INSTITUTE OF AYURVEDA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Presence of Cardinal sign and symptoms of sandhigata Vata and vistabdhajirna along with samanya ajirna lakshana. 2) Digital x-ray depicting the features of osteoarthritis. 3) Patients willing to incorporate themselves in the study. 4)Bone mineral density bmd with T score of -1 or below. 5) Patients who are not receiving any other therapies except the research medicine exclusively for Sandhigata Vata (OA).

Exclusion criteria

Exclusion criteria: 1) Severe cases of osteoarthritis as leading to stiffness and immobility. 2) Patients of sandhigata Vata without symptoms of vistabdhajirna or without giving the history of vistabdhajirna. 3) Any other conditions of the joints and bones like Rheumatoid arthritis and Ankylosing Spondylitis, Tubercular arthritis or infective Arthritis will be excluded. 4) Any malignant condition of the body. 5) Systemic diseases like Diabetes mellitus, Hypothyroidism, Chronic Renal Failure etc.

Design outcomes

Primary

MeasureTime frame
to assess the change in WOMAC Scale for Osteo Arthritis and Parameters assessment scale for Sandhigata vata, at the end of 90 days of drug intervention.Timepoint: at baseline and after 90 days of intervention—

Secondary

MeasureTime frame
Radiological changes through X-Ray, BMD score changes Changes in Advanced Glycation End Product Assessment through ELISA- quantitative method. Timepoint: at baseline and after 90 days of intervention—

Countries

India

Contacts

Public ContactDR SHALINI RAI

All India Institute Of Ayurveda, New Delhi

drmoreanand@gmail.com9422025732

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026